Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL-410
- Development stage
- Preclinical
- Lead developer
- Sola Biosciences
- Modality
- Gene Therapies
01
Overview
SOL-410 is a gene therapy candidate developed by SOLA Biosciences for the treatment of nervous system diseases, with active indications including Alzheimer disease and frontotemporal dementia. Its mechanism of action is based on gene therapy, but specific genetic targets or vectors have not been disclosed in available sources. The drug is currently in preclinical development and has not received any regulatory approvals[1][2][3].
- Other names
- SOL-410SOL410SOL 410
Beyond the preview
Go deeper on SOL-410.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL-410.